Swiss biotech startup FluoSphera raised €1.23M to expand its human-relevant preclinical platform, which aims to predict drug responses more accurately and reduce reliance on animal models.
FluoSphera Secures €1.23M to Expand Human-Based Preclinical Platform
January 12, 2026